SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

Concise Database for Antibody Target, Technology & Pipeline: 1-Year Subscription

 

DUBLIN, Mar. 07, 2014
/PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/cl5vpz/antibody_target) has announced the addition of the "Concise Database for Antibody Target, Technology & Pipeline: 1-Year Subscription" subscription to their offering.

(Logo:http://photos.prnewswire.com/prnh/20130307/600769)

Subscription to La Merie Publishing's proprietary Antibody Database provides online access to information about more than 2,400 project entries for therapeutic antibodies on the market and in research & development. Pre-established and free search functions allow to identify antibodies according to their

  • Technology (e.g. antibody-drug conjugate, bispecific, isotype, phage display)
  • Target (e.g. Her2, CD20, TNF, PD-1/PD-L1)
  • Pipelines (selected by target, therapeutic area, company, technology)
  • Sales (for marketed antibodies)
  • R&D Phase (clinical phases, market, preclinical)
  • Territory (countrywise)
  • Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
  • Drug Code/Name (for individual molecules)

Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic antibodies is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.

  • Special Focus of the Database:
  • Antibody-Drug Conjugates
  • Bispecific Antibodies
  • Biosimilar and Biosuperior Antibodies

Prerequisite: Internet access

Purchase of the subscription provides a 1-year online access to the data of the Antibody Target, Technology & Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.

Benefits from the Antibody Pipeline Database:

  • Intuitive use
  • Designed for structured searches
  • Focused on targets, therapeutic areas and R&D phases
  • Ideal for competitor analysis (companies, targets, technologies, R&D phase)
  • Cost-effective and rapid solution for benchmarking
  • Identification of licensing candidates

For more information visit http://www.researchandmarkets.com/research/cl5vpz/antibody_target

Media Contact: Laura Wood , +353-1-481-1716, [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.